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ABSTRACT 
Lumazine synthase from Brucella spp. (BLS) is a 
highly immunogenic decameric protein. It has been 
previously described as a carrier of peptides or pro- 
teins to increase their immunogenicity in different 
animal species, but its activity has never been evalu- 
ated in chickens. In this work, the use of BLS to im- 
prove the antibody response against bovine rotavirus 
(BRV) VP8d protein in laying hens was assessed. 
VP8d is the inner domain of the VP8 spike protein 
which preserves the sialic acid binding activity and 
the neutralizing epitopes present in the viral protein. 
Hens were immunized three times with 2 μg of VP8d 
alone or fused to BLS. Hens inoculated with BLSVP8d 
developed higher antibody titers (evaluated by ELISA 
and viral neutralization test) than hens immunized 
either with VP8d alone or the mixture of VP8d and 
BLS. Furthermore, IgY antibodies against BLSVP8d 
were able to fully protect mice against challenge with 
virulent BRV in a dose-depent-manner. Overall, these 
results demonstrate that BLS is a potent immonu- 
modulator that enhances the antibody response in 
hens, thus increasing the concentration of specific IgY 
in the egg yolk, one of the main issues to be adressed 
in order to improve the use of the IgY technology.  
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1. INTRODUCTION 
Administration of specific antibodies for prophylaxis and 
therapy of human and animal diseases has been exten- 
sively used. Mammalian antibodies from rabbits, humans, 
mice or horses, among others, have been applied for 
cancer therapy, inactivation of toxic substances such as 
drugs or snake venoms and for the treatment of infec- 
tious diseases. In the last decades, there has been an in- 
creasing interest in the oral administration of specific 
antibodies for infections in the gastrointestinal tract [1].  
This strategy has demonstrated to be successful in the 
treatment and prophylaxis of diseases caused by bacteria, 
viruses or even parasites [2]. However, large scale pro- 
duction of mammalian antibodies is expensive and un- 
easy. To overcome these difficulties, egg yolk antibodies 
are proposed as a low-cost and feasible alternative [3]. 
Since the early 1980’s, egg yolk antibodies have been 
deeply studied [4,5]. IgY is the only immunoglobulin 
isotype present in the egg yolk, the main serum immu- 
noglobulin in birds and it is considered to be ancestral of 
mammals IgG and IgE [4]. The use, production and puri- 
fication of the egg yolk IgY is known as IgY technology 
[6]. IgY technology has several advantages over conven- 
tional mammalian antibody production: chicken housing 
is inexpensive, egg collection is noninvasive and IgY 
isolation is relatively fast and simple [7]. Moreover, due 
to the phylogenetic distance, conserved mammal proteins 
are often more immunogenic in birds than in mammals 
[8]. IgY technology has been evaluated for therapeutic 
application by oral administration to prevent or control 
some enteropathogens such as enterotoxigenic Esche- 
richia coli [9], Salmonella Typhimurium [10], S. En- 
teritidis [11] and rotavirus [12-14]. 
Extensive applications of IgY technology demands the 
optimization of the immunization of hens to produce egg 
yolk antibodies in a cost-effective manner. There are 
several immunization protocols that describe up to six 
immunizations with antigen doses varying from 0.01 to 1 
mg to evoke a strong immune response in order to render 
high concentrations of specific IgY in the egg yolk [4, 
15-18].  
The enzyme lumazine synthase from Brucella spp 
(BLS) has been reported as a carrier for antigen delivery, 
based on its physicochemical and immunogenic proper- 
ties [19]. BLS assembles as a remarkably stable dimer of 
pentamers, with ten N-terminus sites of linkage. Struc- 
tural analysis of this molecule showed that it is possible 
to insert peptides and protein domains without disturbing 
its conformation. It has been reported that BLS possesses 
OPEN ACCESS 
D. Bellido et al. / Advances in Bioscience and Biotechnology 3 (2012) 80-86 81
immunostimulatory properties that enhance both cellular 
and humoral response [20]. BLS presents immune-en- 
hancing properties only when the foreign antigen is co- 
valently attached to it [20]. Considering its multivalence 
and immunogenic properties, BLS has been evaluated as 
a carrier for systemic immunization. Several peptides 
and a small protein domain of 9 kDa were successfully 
coupled by recombinant fusion to the structure of BLS. 
This carrier has also shown to be an efficient adjuvant 
for oral immunization, eliciting a systemic immune re- 
sponse due to its homodecameric arrangement and re- 
markable thermodynamic stability [21]. We have previ- 
ously described the fusion of BLS to the inner domain of 
the VP8 protein (BLSVP8d) from Bovine Rotavirus 
(BRV) strain C486. This fusion protein was able to elicit 
a high antidody response in mice which resulted in fully 
protection of pups against challenge with virulent C486 
BRV [22]. Rotavirus is the major etiological agent of 
severe neonatal gastroenteritis in mammalian species, 
including infants and young children worldwide. It is 
also responsible for extensive economic losses in animal 
species. A survey conducted in Argentina during a 10- 
year period, showed that BRV represents the main patho- 
gen associated to neonatal calf diarrhoea in both beef and 
dairy herds, with 64.5% overall incidence [23]. Calves 
are susceptible to rotavirus infection within the first 2 
weeks of life and, for this reason, active immunization 
prior to exposure to virulent strains is almost impossible 
to accomplish. However, it is well known that the con- 
tinuous presence of high titers of passive RV antibodies 
in the gut lumen (either naturally produced or artificially 
added to the milk) fully protects against diarrhea and 
significantly reduces virus shedding [24-26]. Passive im- 
munity strategies such as oral administration of specific 
antibodies from bovine colostrum or chicken egg yolk 
have been explored and were shown to be effective to 
prevent RV infections in humans and animals [27-30]. 
However, IgY-based immunotherapies appear to be more 
feasible than bovine calostrum-based treatments [30].  
The aim of this work was to test BLS as an alternative 
immunomodulator to improve the antibody response ag- 
ainst BRV-VP8d in laying hens in order to maximize the 
production of specific egg yolk antibodies and to assess 
their performances in a suckling mouse model. 
2. MATERIALS AND METHODS 
2.1. Virus and Cells 
The C486 BRV (P[1]G6) strain was propagated in mon- 
key kidney (MA104) cells. Tissue culture supernatants 
were used in the immunological assays and concentrated 
as described previously [31], for mouse challenge. MA- 
104 cells were provided by the culture Cell Section of 
the Institute of Virology, INTA-Castelar. Cells were 
cultured in complete medium (MEM-D) supplemented 
with 100 U/ml penicillin, 100 μg/ml streptomycin and 
10% heat inactivated FBS.  
2.2. Expression and Purification of Recombinant 
Proteins 
The vectors pET-BLSVP8d (which contains VP8d, the 
62 - 224 region of the VP8 protein, downstream BLS 
gene) and pET-VP8d (which contains only VP8d se- 
quence) were previously generated. Expression and puri- 
fication of the recombinant proteins have also been re- 
ported [22]. Briefly, BLSVP8d and VP8d were expressed 
as inclusion bodies. The inclusion bodies were solubi- 
lised by overnight incubation in a 8 M urea, 50 mM Tris/ 
HCl, 5 mM EDTA, pH 8 buffer, at room temperature 
with agitation. The solubilised proteins were purified by 
anion exchange chromatography in a Q-Sepharose (Phar- 
macia) column under denaturing conditions; elution was 
performed using a linear gradient between 0 and 1M 
NaCl in 8 M urea. The purified proteins were refolded by 
dialysis against a 50 mM Tris/HCl, 150 mM NaCl, 5 mM 
EDTA, 1 mM DTT and 1 mM PMSF, pH 7.4 buffer, at 
4˚C. The peaks enriched with BLSVP8d and VP8d were 
further purified by gel filtration on a Superose 6 (Phar-
macia) and Superdex 75 (Pharmacia) columns, respec-
tively. For BLSVP8d, a third purification step on a Su-
perdex 200 column was performed. The purity of the 
preparations was determined by SDS-PAGE (12%, w/v) 
and quantified by measuring at 280 nm wavelength. The 
purified proteins were dialysed against PBS, frozen in 
liquid N2 and stored at −80˚C. 
2.3. Immunisations of Chickens 
Groups of light brown laying hens (n = 2) seronegatives 
for RV, were immunized with 1) BLSVP8d (fusion pro- 
tein), 2) VP8d and 3) mixture of BLS and VP8 (BLS + 
VP8d). Each group was immunized with 2 μg of VP8d. 
The doses of BLS and BLSVP8d were corrected by their 
molecular weights to inoculate equimolar amounts of 
each protein compared to that of VP8d (0.105 nmol). 
Hens were immunized with three doses of 0.5 ml. 
Vaccines were prepared with Freund’s incomplete adju- 
vant containing the appropriate antigen in a proportion 
adjuvant:antigen of 50:50. Inoculations were performed 
by the intramuscular route at days 0, 30 and 75. Side 
effects in the site of injection and laying capacity were 
checked. 
Eggs were collected on days 0, 21, 30, 45, 52, 60, 75 
and 96 post-first immunization (DPI). 
2.4. Purification of Egg Yolk IgY 
IgY from egg yolk was purified according Akita and 
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Nakai (1990). Briefly, the yolks were diluted with 5 vol- 
umes of distilled water and then frozen at –20˚C. There- 
after, diluted yolks were thawed at 4˚C ON and centri- 
fuged at 8000 g, at 4˚C for 12 min. The pellet was dis- 
carded and 0.24 g/ml of (NH4)2SO4 were added to the 
supernatant, incubated for 30 min at room temperature 
with slightly stirring and then centrifuged at 10,000 g, 
4˚C, 12 min. The pellet was resuspended in (NH4)2SO4 2 
M, for 30 min at room temperature and centrifuged as 
above. Finally, the supernatant was discarded, the pellet 
was resuspended in PBS and then the solution was dial- 
ised ON against PBS at 4˚C. Concentration of purified 
IgY was measured by NanoDrop (ND1000, Thermo Sci- 
entific).  
2.5. SDS-PAGE and Western Blot (WB) 
Purified IgY were electrophorezed on SDS-PAGE (12%) 
and stained with Coomassie blue.  
To test the specificity of the purified IgY anti-BLS- 
VP8d, an indirect WB was performed. BLSVP8d and 
VP8d extracts were subjected to SDS-PAGE (15%), 
blotted onto an Immobilon P membrane (Millipore) and 
blocked ON with PBS Tween 0.1% (PBS-T) and skim 
milk 3%. All subsequent steps were carried out using this 
buffer. The membrane was then incubated 1 h at 37˚C 
with the purified IgY solution, washed three times and 
finally incubated 1h at 37˚C with HRP-labeled goat anti- 
chicken IgY (Sigma®) for 1 h at 37˚C. After washing 
three times, the WB was revealed by DAB/H2O2 system 
(Sigma®). As negative control a non induced bacteria 
culture was included. 
2.6. Elisa 
Titers of IgY against VP8d were determined according to 
Bellido et al. [22]. Briefly, purified VP8d was directly 
adsorbed onto the plate (1 μg/well) in carbonate-bicar- 
bonate buffer pH 9.6 and blocked with PBS-T, 5% nor- 
mal horse serum (blocking buffer) for 1 h at 37˚C. 
Thereafter, 4-fold dilutions of all IgY samples in block- 
ing buffer were incubated for 1 h at 37˚C. Plates were 
washed with PBS-T and incubated with HRP-labeled 
goat anti-chicken IgY (Sigma®). The reaction was re- 
vealed by ABTS/H2O2 system and stopped by the addi- 
tion of 5% (w/v) SDS. Absorbance was measured at 405 
nm (A405) in a Multiskan Ex, Labsystems Inc. The cut 
off value of the assay was calculated as the mean specific 
optical density (OD) plus 3 standard deviations from IgY 
purified samples obtained from 6 unimmunised hens. 
As a positive control, a previously purified IgY against 
Human RV WA strain, which partially cross-reacts with 
VP8d C486 BRV, was used. 
Titers were expressed as the reciprocal of the highest 
IgY dilution with an OD value above the cut off. 
2.7. Viral Neutralization (VN) Test 
Virus neutralizing titers were determined by fluorescent 
focus reduction test as described by To et al. [31] with 
modifications. Serial diluted samples of the purified IgY 
were incubated with C486 strain BRV at 37˚C for 1 h, 
then they were inoculated onto MA104 cells and further 
incubated. Fluorescent focus-forming units (FFU) were 
evaluated by a direct immunofluorescent assay, and neu- 
tralization titers were expressed as the reciprocal of the 
highest dilution showing >80% reduction of FFU. 
2.8. RV Protection Assay in Newborn Mice 
Three groups of 10 four-day-old BALB/c mouse pups 
received 100 μl of a solution containing: 0.5 mg, 0.1 mg 
or 0.05 mg of IgY anti-BLSVP8d purified from eggs 
collected from both hens on day 96. Another group of 
mice received 2.5 mg of IgY anti-WA per pup. This dose 
was previously demonstrated to have the same neutraliz- 
ing activity in vitro as 0.5 mg of IgY anti-BLSVP8d.  
As negative control a group received 0.5 mg of IgY 
purified from unimmunized hens and a placebo group 
only received sterile PBS. Each treatment was adminis- 
tered by intragastric route using a flexible plastic feeding 
tube. Treatments were administered once a day for 4 
days.  
During the second day of the trial and 1 h after the 
treatment, pups were orally challenged with 6 × 105 
fluorescent focus units (FFUs) (corresponding to 30 di- 
arrhea doses 50—DD50) of virulent C486 BRV per mouse. 
This infective virus dose produced diarrhea in 100% 
control naïve animals [22]. Pups were inspected for di- 
arrhea at 24, 48 and 72 h after challenge by gentle palpa- 
tion of the abdomen [32,33]. After the last inspection, 
mice were euthanized. The trial was carried out in dupli- 
cate in two independent assays.  
The Fisher exact test was used to compare the propor- 
tions of pups with diarrhoea among the various groups. P 
values lower than 0.01 were considered significant. 
Hens’ management, inoculation and sample collection 
were conducted by trained personnel under the supervi- 
sion of a veterinarian and in accordance with protocols 
approved by the INTA’s ethical committee of animal 
welfare (N˚ 37). 
3. RESULTS AND DISCUSSION 
Efficiency of the immunization of hens is a key issue that 
must be addressed to maximize the amount of specific 
IgY that can be obtained from the egg yolk. 
In this context, novel immunomodulators should be 
explored, not only to increase the production of antibod- 
ies but also to reduce undesirable and painful side effects 
in the birds due to the inoculation [34]. In this work the 
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potential use of the enzyme lumazine synthase (BLS) as 
an immunomodulator to increase the antibody response 
in laying hens was tested.  
Based on our promising results obtained in mice [22], 
BLSVP8d fusion protein was selected as antigen, since it 
was able to induce a strong antibody response using low 
amounts of protein. In this work immunizations were 
carried out using 2 μg of VP8d, this dose was 100 times 
lower than the dose used by Kovacs Nolan et al. (2001) 
to produce IgY against VP8 with high neutralization ac-
tiveity [15]. 
In all hens, a single immunization was enough to de- 
tect IgY anti-VP8d in the yolks. The presence of IgY 
after purification was confirmed by SDS-PAGE (Figure 
1(a)) and the final concentration of IgY was 5 mg/ml. 
The western blot analysis showed that the IgY was able 
to recognize specifically both the fusion protein BLSVP8d 
and the monomeric protein VP8d (Figure 1(b)).  
The content of specific IgY in the egg extracts was 
measured by ELISA and VN assay.  
According to ELISA, specific IgY were first detected 
in all groups at day 30 post-immunization (pi). After the 
first booster, titers of hens immunized with VP8 ranged 
between 40 and 1000 from days 45 to 60. At day 75, 
titers declined and after the second booster, levels of 
antibodies increased to their previous values. Develop- 
ment of the immune response of hens induced by BLS + 
VP8d was similar to the response of the hens immunized 
with the monomeric protein alone and titers ranged be- 
tween 40 and 4000. BLSVP8d evoked a stronger im- 
mune response than VP8d or BLS + VP8d. Antibody titers 
of hens immunized with BLSVP8d ranged between 1000 
and 16,000 (Figure 2). Antibody titers of all hens from 
VP8d and BLS + VP8d groups decreased at least a 4-fold 
dilution 45 days after the second inoculation. In contrast, 
antibody levels from one of the two hens immunised 
with BLSVP8d slightly increased. This finding suggests 
that the protein fused to BLS is able to maintain a long- 
lasting immune response and, consequently, the number 
of booster immunizations could be reduced. As expected, 
after the third immunization, titers of specific antibodies 
increased and hens immunized with BLSVP8d showed 
the highest titers (Figure 2).  
Although IgY was produced against a single domain 
of VP8, the VN assay confirmed that anti-VP8d IgY was 
able to neutralize the activity of C486 BRV. Neutralizing 
IgY from all groups was first detected on day 45 pi and, 
from this day onwards, hens immunized with the fusion 
protein developed the highest neutralization titers: VN 
titers in VP8d or BLS + VP8d groups ranged between 4 
and 64 respectively while titers from BLSVP8d group 
ranged between 250 and 1000. The kinetics of the re- 
sponse assayed by VN was similar to the kinetics deter-
mined by ELISA (Figure 3). 
 
(a)                        (b) 
Figure 1. (a) SDS-PAGE in 12% (w/v) polyacrylamide analy- 
sis of purified IgY. Lane 1: molecular weight marker (MWM); 
lane 2: unpurified egg yolk; lane 3: purified BLSVP8d IgY and 
lane 4: purified C-IgY; (b) Wetern blot analysis of anti- 
BLSVP8d IgY. VP8d and BLSVP8d proteins extracts were run 
on SDS-PAGE, transferred onto PVDF membrane and probed 
with anti-BLSVP8d IgY. Lane 1: MM; lane 2: Mock; lane 3: 
VP8d and lane 4: BLSVP8d. 
 
 
Figure 2. Detection of specific IgY antibodies in egg yolk from 
immunized hens. Purified IgY response developed by hens 
immunized with VP8d (empty bars), BLS + VP8d (striped bars) 
and BLSVP8d (solid bars) was evaluated by ELISA. Titers 
were expressed as the reciprocal of the highest IgY dilution 
which gave an OD value above the mean of the OD values of 
the negative samples plus 3 standard deviations. Arrows in the 
top of the figure indicate immunization days. 
 
 
Figure 3. Evaluation of the neutralizing activity of the purified 
IgY. Neutralization titers of IgY from hens immunized with 
VP8d (empty bars), BLS + VP8d (striped bars) and BLSVPd 
(solid bars) are expressed as the reciprocal of the highest dilu- 
tion showing a 80% reduction of FFU. Arrows in the top of the 
figure indicate immunization days. 
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Immunogenicity of any antigen could be increased 
when it is fused to BLS since it can be incorporated at 10 
different points due to the polymeric nature of the im- 
munomodulator. This scaffold stimulates the immune 
system, that has evolved to respond strongly to repetitive 
and spatially ordered antigens, typically found on micro- 
bial surfaces [35,36]. BLS is able to elicit long-lasting 
humoral and cellular response by several mechanisms. 
For example, BLS can induce a strong signal transduc- 
tion mediated by B-cell receptors and it also activates the 
cellular response by delivering CD8+ T-cell epitopes into 
the MHC class I pathway. Moreover, BLS also activates 
and induces the proliferation of dendritic cells via TLR4 
[37,38]. In this work, hens immunized with BLSVP8d 
developed high titers of antibodies, even using low 
amounts of the antigen. This work demonstrates that fu- 
sion of VP8d antigen to BLS is able to increase the spe- 
cific humoral response not only in mammals but also in 
birds, even if different immunological mechanisms are 
involved. Indeed, 5 μg of IgY from hens immunized with 
BLSVP8d were able to block infection of MA-104 cells 
with bovine rotavirus C486.  
Since higher neutralization titers were found in the 
hens immunized with the fusion protein, these antibodies 
were further tested in vivo in a mouse model of rotavirus 
disease. Mice from the groups that received 0.5 mg or 
0.1 mg were fully protected 48 h and 72 h post-challenge 
(pc) (P = 0.0001) and the lowest dose assayed, 0.05 mg, 
was able to protect 80% of the pups 72 hours pc (P = 
0.0086).  
In contrast, IgY anti-WA protected 20%, 50% and 
70% of the mice at 24, 48 and 72 h pc (P = 0.032), re- 
spectively. All mice from the placebo group and 80% of 
the mice from the control group showed symptoms of 
diarrhoea (Table 1). Protection rates observed were 
similar in both trials. 
 
Table 1. RV protection assay in newborn mice. 
Percentage of protection against diarrhea
Treatment 
24 h 48 h 72 h 
BLSVP8d 0.5 mg 80% 100% 100%a 
BLSVP8d 0.1 mg 40% 100% 100%a 
BLSVP8d 0.05 mg 40% 40% 80%a 
WA 2.5 mg 20% 50% 70%a 
C-IgY 0.1 mg 10% 10% 20%b 
C-PBS 0% 0% 0%b 
Protection rate against diarrhea achieved by purified IgY. Pups were fed 
with different doses of BLSVP8d IgY, control IgY or PBS and challenged 
with BRV. The development of diarrhea was monitored daily for up to 72 h 
postchallenge. The experiment was performed in two independent assays 
with ten mice per group. Different letters within columns indicate signi- 
ficant differences. 
These results show that IgY-BLSVP8d was able to 
protect newborn mice from rotavirus disease in a dose- 
dependent and efficient manner. Sarker et al. (2007), also 
found that a dose of 100 μg of IgY produced against hu- 
man rotavirus was enough to provide high protection 
levels (94% of protection at 96 hours pc) in the suckling 
mouse model [13]. 
This work demonstrates that BLS is a suitable immu- 
nomodulator that could be used to produce high levels of 
egg yolk IgY using low amounts of antigen and few im- 
munizations. Therefore, BLS could be use to obtain IgY 
against low-immunogenic recombinant proteins and it 
becomes also appropriate for large-scale production of 
IgY, thus improving potential applications of IgY tech- 
nology. Further studies should include the evaluation of 
the use of BLS combined with other adjuvants specially 
designed for poultry. 
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